XML 71 R50.htm IDEA: XBRL DOCUMENT
v3.25.1

ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Narrative (Details) $ / shares in Units, $ in Millions |  |  |  |  | 3 Months Ended | 12 Months Ended | 36 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Mar. 10, 2025 USD ($) $ / shares | Mar. 18, 2024 USD ($) $ / shares | Feb. 26, 2024 USD ($) $ / shares | Jan. 23, 2024 USD ($) right $ / shares | Mar. 31, 2025 USD ($) | Mar. 31, 2024 USD ($) | Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2026 | Feb. 28, 2025 USD ($)
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |
Business combination, contingent value, number of rights received | right |  |  |  | 1 |  |  |  |  |  |
Diabetes business - royalties |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |
Percentage of net sales payable to alliance partner |  |  |  |  | 14.00% |  | 15.00% |  |  |
BioArctic |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |
License and other arrangements upfront payments |  |  |  |  | $ 100 |  |  |  |  |
Maximum aggregate contingent and regulatory milestone payments |  |  |  |  |  |  |  |  |  | $ 1,300
Keytruda royalties |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |
Percentage of net sales payable to alliance partner |  |  |  |  |  |  |  | 6.50% |  |
Keytruda royalties | Forecast |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |
Percentage of net sales payable to alliance partner |  |  |  |  |  |  |  |  | 2.50% |
Keytruda royalties | Forecast | Bristol-Myers Squibb |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |
Payment and royalty allocation |  |  |  |  |  |  |  |  | 75.00% |
Keytruda royalties | Forecast | Ono |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |
Payment and royalty allocation |  |  |  |  |  |  |  |  | 25.00% |
RayzeBio |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |
Share price (in usd per share) | $ / shares |  |  | $ 62.50 |  |  |  |  |  |  |
Total consideration |  |  | $ 4,147 |  |  |  |  |  |  |
Business combination, consideration transferred |  |  | 3,600 |  |  |  |  |  |  |
RayzeBio | Unvested Equity Awards |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |
Total consideration |  |  | $ 274 |  |  |  |  |  |  |
Mirati Therapeutics |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |
Share price (in usd per share) | $ / shares |  |  |  | $ 58.00 |  |  |  |  |  |
Total consideration |  |  |  | $ 4,801 |  |  |  |  |  |
Business combination, consideration transferred |  |  |  | $ 4,100 |  |  |  |  |  |
Business combination, contingent value, share price (in dollars per share) | $ / shares |  |  |  | $ 12.00 |  |  |  |  |  |
Continent consideration liability |  |  |  | $ 1,000 |  |  |  |  |  |
Business combination, contingent value payout, period |  |  |  | 7 years |  |  |  |  |  |
2seventy bio |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |
Share price (in usd per share) | $ / shares | $ 5.00 |  |  |  |  |  |  |  |  |
Total consideration | $ 286 |  |  |  |  |  |  |  |  |
Business combination, consideration transferred | $ 100 |  |  |  |  |  |  |  |  |
Karuna |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |
Asset acquisition, share price (in dollars per share) | $ / shares |  | $ 330.00 |  |  |  |  |  |  |  |
Payments for asset acquisitions |  | $ 14,027 |  |  |  |  |  |  |  |
Payments for asset acquisitions, net of cash acquired |  | 12,900 |  |  |  |  |  |  |  |
Karuna | Vested Equity Awards |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |
Payments for asset acquisitions |  | 1,100 |  |  |  |  |  |  |  |
Karuna | Unvested Equity Awards |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |
Payments for asset acquisitions |  | $ 289 |  |  |  |  |  |  |  |
Karuna | Acquired IPRD |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |
Payments for asset acquisitions |  |  |  |  |  | $ 12,100 |  |  |  |

X
- Definition Asset Acquisition, Share Price + References No definition available. + Details
Name: | bmy_AssetAcquisitionSharePrice
Namespace Prefix: | bmy_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Business Combination, Number Of Rights Received Per Share + References No definition available. + Details
Name: | bmy_BusinessCombinationContingentValueNumberOfRightsReceived
Namespace Prefix: | bmy_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Business Combination, Contingent Value Payout, Period + References No definition available. + Details
Name: | bmy_BusinessCombinationContingentValuePayoutPeriod
Namespace Prefix: | bmy_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Business Combination, Contingent Value, Share Price + References No definition available. + Details
Name: | bmy_BusinessCombinationContingentValueSharePrice
Namespace Prefix: | bmy_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Contingent and Regulatory Milestone Payments, Maximum Aggregate + References No definition available. + Details
Name: | bmy_ContingentAndRegulatoryMilestonePaymentsMaximumAggregate
Namespace Prefix: | bmy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition License and Other Arrangements Upfront Payments + References No definition available. + Details
Name: | bmy_LicenseAndOtherArrangementsUpfrontPayments
Namespace Prefix: | bmy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Licensing Arrangements + References No definition available. + Details
Name: | bmy_LicensingArrangementsLineItems
Namespace Prefix: | bmy_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment And Royalty Allocation + References No definition available. + Details
Name: | bmy_PaymentAndRoyaltyAllocation
Namespace Prefix: | bmy_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payments For Asset Acquisitions + References No definition available. + Details
Name: | bmy_PaymentsForAssetAcquisitions
Namespace Prefix: | bmy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments for Asset Acquisitions, Net Of Cash Acquired + References No definition available. + Details
Name: | bmy_PaymentsForAssetAcquisitionsNetOfCashAcquired
Namespace Prefix: | bmy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage Of Net Sales Payable To Alliance Partner + References No definition available. + Details
Name: | bmy_PercentageOfNetSalesPayableToAlliancePartner
Namespace Prefix: | bmy_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionSharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bmy_DiabetesBusinessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bmy_BioArcticMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bmy_LicensingAndOtherArrangementsAxis=bmy_KeytrudaRoyaltiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bmy_BristolMyersSquibbMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bmy_OnoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=bmy_RayzeBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=bmy_UnvestedEquityAwardsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=bmy_MiratiTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=bmy_A2seventyBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=bmy_KarunaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=bmy_VestedEquityAwardsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=bmy_AcquiredIPRDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |